M413 Covid-19 in a Patient With Cvid and Contraindications to Several Potential Treatments

Ender, E.; Timothy, Priyanka

doi:10.1016/j.anai.2020.08.360

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reflecting the relative frequency of humoral immunodeficiencies among IEIs, the majority of patients who experienced COVID-19 are affected by antibody deficiency ( n = 330, 51%) [ 5 ▪ , 9 ▪ , 10 , 12 – 17 , 19 , 24 , 26 , 28 , 30 , 33 , 34 , 36 , 37 , 42 , 44 , 45 , 48 , 52 , 53 , 55 , 57 – 62 , 64 , 66 – 69 ]. Among them, 200 have common variable immunodeficiency (CVID, 60% of all antibody deficiencies), 59 have X-linked agammaglobulinemia (XLA, 18%) and eight have autosomal recessive agammaglobulinemia (2%).…”

Section: Overview Of Reports Of Coronavirus Disease 2019 In Patients With Inborn Errors Of Immunitymentioning

confidence: 99%

“…We here analyze the published case series and single cases describing the outcome of COVID-19 in patients with IEIs. Removing duplicate patients, to the best of our knowledge, we count a total of 649 reported patients with IEI who were infected with SARS-CoV-2, spanning all subgroups of immune defects as defined by the International Union of Immunological Societies committee for IEI (Table 1) [1 ▪▪ ,3,4,5 ▪ ,9 ▪ ,10–65]. Patients were mostly included based on a positive molecular test, antigenic test, or serology, although some reports also include patients with symptoms and clinical imaging compatible with a diagnosis of COVID-19, with or without a history of exposure to infected individuals [10,12,14,15,18].…”

Section: Overview Of Reports Of Coronavirus Disease 2019 In Patients ...mentioning

confidence: 99%

“…& ,10, [12][13][14][15][16][17]19,24,26,28,30,33,34,36,37,42,44,45,48,52,53,[57][58][59][60][61][62]64,[66][67][68][69]. Among them, 200 have common variable immunodeficiency (CVID, 60% of all antibody deficiencies), 59 have X-linked agammaglobulinemia (XLA, 18%) and eight have autosomal recessive agammaglobulinemia (2%).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned

Bucciol

Tangye

Meyts

2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused extreme concern for patients with inborn errors of immunity (IEIs). In the first 6 months of the pandemic, the case fatality rate among patients with IEIs resembled that of the general population (9%). This review aims at summarizing what we have learned about the course and outcome of coronavirus disease 2019 (COVID-19) in patients with different IEIs and what this can potentially teach us about the immune mechanisms that could confer protection or predisposition to severe disease. Recent findings A total of 649 patients with IEI and COVID-19 have been reported in the last year and a half, spanning all groups of the International Union of Immunological Societies classification of IEIs. For most patients, the underlying IEI does not represent an independent risk factor for severe COVID-19. In fact, some IEI may even be protective against the severe disease due to impaired inflammation resulting in less immune-mediated collateral tissue damage. Summary We review the characteristics of SARS-CoV-2 infection in a large number of patients with IEI. Overall, we found that combined immunodeficiencies, immune dysregulation disorders, and innate immune defects impairing type I interferon responses are associated with severe disease course.

show abstract

Section: Overview Of Reports Of Coronavirus Disease 2019 In Patients With Inborn Errors Of Immunitymentioning

confidence: 99%

Section: Overview Of Reports Of Coronavirus Disease 2019 In Patients ...mentioning

confidence: 99%

See 1 more Smart Citation

Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned

Bucciol

Tangye

Meyts

2021

Current Opinion in Pediatrics

View full text Add to dashboard Cite

show abstract

“…Early reports on large and small cohorts of inborn errors of immunity (IEI) patients [6 ▪ ] reported low numbers of infected patients and a wide variability of clinical manifestations, ranging from asymptomatic and mild to moderate symptoms [7–9]. Only a minority of patients develop severe to critical symptoms, fatal in about 10% of them.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 in complex common variable immunodeficiency patients affected by lung diseases

Milito

Soccodato

Auria

et al. 2021

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewIn the general population, the risk of severe COVID-19 is associated with old age, male sex, hypertension, obesity and chronic diseases. Chronic lung diseases are listed as additional risk factors for hospitalization and ICU admission. The purpose of this review is to define whether chronic lung diseases, such as bronchiectasis and interstitial diseases, represent a risk for a severe SARS-CoV-2 infection in patients affected by common variable immunodeficiency (CVID), the most common symptomatic primary antibody defect. Recent findingsCVID patients with SARS-CoV-2 infection have been reported since the beginning of the pandemic with a wide range of clinical presentations ranging from asymptomatic to mild/moderate and severe COVID-19. The meta-analysis of 88 CVID cases described in large cohorts and case reports demonstrated that CVID patients with chronic lung involvement have an increased risk for severe COVID-19 in comparison to CVID without lung diseases (50 vs. 28%, relative risk 1.75, 95% confidence interval 1.04-2.92, P ¼ 0.043). Differently from the general population, age and metabolic comorbidities did not represent a risk factor for severe course in this patient's population.

show abstract

M413 Covid-19 in a Patient With Cvid and Contraindications to Several Potential Treatments

Cited by 2 publications

References 0 publications

Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned

Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned

COVID-19 in complex common variable immunodeficiency patients affected by lung diseases

Contact Info

Product

Resources

About